A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: lapatinib/herceptin
Sponsor: Peking Union Medical College Hospital
Collaborators: Taizhou EOC Pharma Co., Ltd.